Literature DB >> 12586573

Pharmacokinetics of the antimicrobial agents rifampicin and miconazole released from a loaded central venous catheter.

A F E Rump1, K Güttler, D P König, N Yücel, M Korenkov, J M Schierholz.   

Abstract

The time course of rifampicin and miconazole concentrations after insertion of a polyurethane catheter loaded with these antibiotics were studied. Data from controlled release experiments in vitro were used, and the concentration time courses of the antimicrobials in serum were calculated by pharmacokinetic simulations. Systemic therapy using typical dosages (rifampicin 600 mg/day iv, miconazole 3 x 200 mg/day iv) results in rifampicin concentrations between 54 and 8424 microg/L, and miconazole concentrations between 3567 and 4676 microg/L. After insertion of a polyurethane catheter loaded with these antibiotics, the maximal concentrations after catheter placement were determined as 6 microg/L at 10.7h for rifampicin, and 13 microg/L at 28.6 h for miconazole. Assuming that the total amount of antibiotics incorporated in the catheter matrix were bioavailable ('worst case'), the resulting maximal concentrations calculated by simulation are 10 microg/L for rifampicin and 65 microg/L for miconazole. Maximal concentrations of rifampicin or miconazole resulting from the insertion of a polyurethane catheter loaded with these antibiotics are, therefore, far below the concentrations resulting from a systemic therapy with the same antimicrobial agents. Even in the worst case, the danger of selecting resistant bacterial strains seems remote because the systemic drug levels are magnitudes of order below subinhibitory concentrations. Copyright 2003 The Hospital Infection Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586573     DOI: 10.1053/jhin.2002.1358

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  3 in total

1.  Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.

Authors:  Albrecht Serfling; Johannes Wohlrab; Holger B Deising
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

2.  Anti-Candida activity of antimicrobial impregnated central venous catheters.

Authors:  L Cobrado; A Silva-Dias; M M Azevedo; A Rodrigues
Journal:  Antimicrob Resist Infect Control       Date:  2017-11-03       Impact factor: 4.887

3.  Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT.

Authors:  Ruth Gilbert; Michaela Brown; Rita Faria; Caroline Fraser; Chloe Donohue; Naomi Rainford; Alessandro Grosso; Ajay K Sinha; Jon Dorling; Jim Gray; Berit Muller-Pebody; Katie Harron; Tracy Moitt; William McGuire; Laura Bojke; Carrol Gamble; Sam J Oddie
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.106

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.